惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

U
Unit 42
Vercel News
Vercel News
博客园 - 叶小钗
大猫的无限游戏
大猫的无限游戏
MyScale Blog
MyScale Blog
P
Proofpoint News Feed
量子位
Engineering at Meta
Engineering at Meta
B
Blog RSS Feed
博客园 - 【当耐特】
Recent Announcements
Recent Announcements
Google DeepMind News
Google DeepMind News
D
DataBreaches.Net
Stack Overflow Blog
Stack Overflow Blog
博客园 - 聂微东
小众软件
小众软件
Hugging Face - Blog
Hugging Face - Blog
人人都是产品经理
人人都是产品经理
IT之家
IT之家
T
The Blog of Author Tim Ferriss
Last Week in AI
Last Week in AI
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
Jina AI
Jina AI
博客园 - 三生石上(FineUI控件)

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Trans...
2026-05-13 · via All Articles on Seeking Alpha

OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call May 12, 2026 4:30 PM EDT

Company Participants

Stephen Silvestro - CEO & Director
Edward Stelmakh - Chief Financial & Strategic Officer
Andrew D'Silva - Chief Business Officer

Conference Call Participants

Jared Haase - William Blair & Company L.L.C., Research Division
Jeffrey Garro - Stephens Inc., Research Division
David Grossman - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Operator

Good afternoon, everyone and thank you for joining OptimizeRx's First Quarter Fiscal 2026 Earnings Conference Call. With us today is Chief Executive Officer, Stephen Silvestro. He is joined by Chief Financial and Strategy Officer, Edward Stelmakh; Chief Legal and Administrative Officer, Marion Odence-Ford; and Chief Business Officer, Andrew D'Silva.

At the conclusion of today's call, I will provide some important cautions regarding the forward-looking statements made by management during today's call. The company will also be discussing certain non-GAAP financial measures, which it believes are useful in evaluating the company's operating results. A reconciliation of such non-GAAP financial measures is included in the earnings release the company issued this afternoon as well as in the Investor Relations section of the company's website. I would like to remind everyone that today's call is being recorded and will be made available for replay as an audio recording of this conference call on the Investor Relations section of the company's website.

Now I would like to turn the call over to OptimizeRx CEO, Stephen Silvestro. Mr. Silvestro, please go ahead.

Stephen Silvestro
CEO & Director

Thank you, operator and good afternoon to everyone joining us for today's first quarter 2026 earnings call.

We delivered a solid start to the year, which exceeded consensus estimates on the top and bottom line. Revenue for the first quarter was $19.8 million and adjusted EBITDA was $3.3 million. While we're pleased with our performance in the quarter, the